510(k) Report

510(k) · Cleared

Cleared

LIAISON Anti-HAV; LIAISON XS

K223403510(k) SpecialCleared Dec 9, 202230-day reviewClass II21 CFR 866.3310

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

DiaSorin, Inc. · LOL Hepatitis A Test (Antibody And Igm Antibody)

Cleared on Dec 9, 2022 as substantially equivalent to K210272 (DiaSorin, Inc., 2021) after a 30-day review. Its family tree reaches back 2 generations to 2020.

Decided
Dec 9, 2022
Review
30 days
Class
Class II
Product code
LOL
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K193532 (2020). No later device cites it as a predicate yet.

  1. Root · 2 generations backK193532 LIAISON Anti-HAV AssayDiaSorin, Inc. · 2020
  2. 1 generation backK210272 LIAISON Anti-HAVDiaSorin, Inc. · 2021
  3. This deviceK223403 LIAISON Anti-HAV; LIAISON XSDiaSorin, Inc. · 2022
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K193532LIAISON Anti-HAV AssayDiaSorin, Inc.2020—
−1K210272LIAISON Anti-HAVDiaSorin, Inc.2021—
0 (this device)K223403LIAISON Anti-HAV; LIAISON XSDiaSorin, Inc.2022—
FIG. 1 — Lineage of K223403, 2020–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LOL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LOL device

  1. #1 K251995 Access anti-HAV IgMscore 13.7 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K210272LIAISON Anti-HAV
Summary page 4
…LOL JJF Predicate Device: LIAISON® Anti-HAV, LIAISON® XS (K210272) Device Description LIAISON® XS Analyzer The DiaSorin LIAISON® XS Analyzer is a fully automated, closed, continuous loading of…
DiaSorin, Inc.2021—
†K193532LIAISON Anti-HAV AssayDiaSorin, Inc.2020—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 2 years and passes through 1 company; a new generation was cleared every 1.8 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All LOL devices

LOL Hepatitis A Test (Antibody And Igm Antibody): FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · LOL

1in 2025

2007: 32008: 32009: 22010: 22011: 12012: 12014: 22016: 22019: 12020: 12021: 12022: 12023: 12025: 12026 (partial year): 2
2007high 3 (2007) · low 0 (2013)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LOL

108in 2008

2007: 182 days median2008: 108 days median
2007high 182 (2007) · low 108 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LOL

2in 2019

2007: 22008: 12009: 12011: 12018: 12019: 2
2007high 2 (2007) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LOL

19in 2025

2007: 22008: 132009: 242010: 532011: 3532012: 422013: 492014: 192015: 292016: 362017: 262018: 612019: 512020: 1042021: 122022: 172023: 362024: 212025: 19
2007high 353 (2011) · low 2 (2007)2025

MAUDE reports naming product code LOL, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007318222
20083108113
20092—124
20102—053
20111—1353
20121—042
20130—049
20142—019
20150—029
20162—036
20170—026
20180—161
20191—251
20201—0104
20211—012
20221—017
20231—036
20240—021
20251—019
20262—0—

What is it indicated for?

The LIAISON® Anti-HAV assay is an in vitro chemiluminescent immunoassay intended for the qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma samples using the LIAISON® Analyzer family*. The assay is indicated as an aid in the laboratory diagnosis of current or previous HAV infections in conjunction with other serological and clinical information and to determine the presence of an antibody response to HAV in vaccine recipients.

This assay is not intended for screening blood or solid or soft tissue donors.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K223403: LIAISON Anti-HAV; LIAISON XS.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K223403

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026